The US Food and Drug Administration has granted Fast Track Designation to myeloma candidate HDP-101 from Heidelberg Pharma.  The designation was supported by nonclinical data as well as clinical data from the ongoing Phase I/IIa study with HDP-101, evaluating the safety and antitumour activity of the candidate in patients with relapsed or refractory multiple myeloma.   […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!